Related Experiment Videos

Diagnosis and management of synovial sarcoma

R Lor Randall1, Kathryn L S Schabel, Ying Hitchcock

  • 1Sarcoma Services, Suite 4260, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA. r.lor.randall@lsc.utah.edu

Current Treatment Options in Oncology
|October 26, 2005
PubMed

Insights

Synovial sarcoma shows moderate response to chemotherapy but requires targeted therapies. Future research should focus on molecular targets, particularly the X,18 translocation fusion protein, for effective treatment development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Synovial sarcoma is a rare soft tissue tumor.
  • Current treatments include surgery and chemotherapy (ifosfamide, doxorubicin) with moderate response rates.
  • The tumor has a characteristic diagnostic translocation (X;18) and chimeric protein.

Purpose of the Study:

  • To highlight the need for targeted therapies in synovial sarcoma.
  • To emphasize the importance of understanding the tumor's molecular characteristics.
  • To advocate for dedicated clinical trials focusing on novel molecular targets.

Main Methods:

  • Review of current treatment strategies and outcomes for synovial sarcoma.
  • Analysis of the molecular underpinnings of synovial sarcoma, including the X;18 translocation.
  • Discussion of potential therapeutic targets and novel agent development.

Main Results:

  • Synovial sarcoma exhibits moderate chemosensitivity (~50% response to ifosfamide/doxorubicin).
  • The X;18 translocation and its resulting chimeric protein are key diagnostic and potentially therapeutic features.
  • Current trial designs combining synovial sarcoma with other soft tissue sarcomas may limit therapeutic advancement.

Conclusions:

  • Advancements in synovial sarcoma treatment necessitate a shift from broad soft tissue sarcoma trials to targeted approaches.
  • Further research into the X;18 fusion protein and overexpressed proteins is crucial.
  • Development of novel agents targeting these molecular pathways, validated through carefully designed clinical trials, is essential for improving patient outcomes.

Related Concept Videos

Appendicitis-II: Diagnostic Studies and Management01:29

Appendicitis-II: Diagnostic Studies and Management

Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...